Figures & data
Figure 2 The pooled absolute rate of pCR for the concurrent (A) and nonconcurrent (B) use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.
![Figure 2 The pooled absolute rate of pCR for the concurrent (A) and nonconcurrent (B) use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.](/cms/asset/db9bff3e-35e7-48a2-b9e0-6ca04627f8ea/dtcr_a_176214_f0002_b.jpg)
Figure 3 The pooled OR of the pCR for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.
![Figure 3 The pooled OR of the pCR for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.](/cms/asset/574c5c21-859c-4285-a38c-77a13231ce48/dtcr_a_176214_f0003_b.jpg)
Figure 4 The pooled OR of secondary outcomes for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.
![Figure 4 The pooled OR of secondary outcomes for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.](/cms/asset/e337e732-68a0-4fe7-b271-6f0b6118f78d/dtcr_a_176214_f0004_c.jpg)